Diffusion-weighted imaging and FDG PET/CT: predicting the prognoses with apparent diffusion coefficient values and maximum standardized uptake values in patients with invasive ductal carcinoma by Bo Choi et al.
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Choi et al. World Journal of Surgical Oncology 2012, 10:126
http://www.wjso.com/content/10/1/126RESEARCH Open AccessDiffusion-weighted imaging and FDG PET/CT:
predicting the prognoses with apparent diffusion
coefficient values and maximum standardized
uptake values in patients with invasive ductal
carcinoma
Bo Bae Choi1, Sung Hun Kim2*, Bong Joo Kang2, Ji Hye Lee2, Byung Joo Song3, Seung Hee Jeong4 and
Hyeon Woo Yim4Abstract
Background: FDG PET/CT and DWI are both functional modalities that indirectly represent the biological
characteristics of cancer, but there are few studies exploring the association between the two modalities and
prognostic factors. Our study attempted to evaluate the mutual association by comparing the prognostic factors,
SUVmax value of PET/CT, and ADC values associated with diffusion imaging in invasive ductal carcinoma (IDC)
patients.
Methods: Patients with pathologically confirmed IDC were recruited. There were 118 patients who underwent MRI,
including DWI, FDG PET/CT, and immunohistochemical staining of the surgical specimen. Histologic analysis was
done on tumor size, lymph node metastasis, expression of estrogen receptors (ER), progesterone receptors (PR),
human epidermal growth factor receptor 2 (HER2), Ki-67, and epidermal growth factor receptors (EGFR). The
relationship among ADC values, SUVmax and prognostic factors were evaluated.
Results: There was significant association between the ADC value and ER-positive and HER2-negative expression.
Significant associations were noted between SUVmax and tumor size, lymph node metastasis, histologic grade, ER
and PR expression, EGFR and Ki-67. However, there was no significant correlation between the ADC value and
SUVmax.
Conclusions: Even though there was no correlation between ADC and SUVmax, both indexes are useful for
predicting the prognosis of IDC.
Keywords: Invasive ductal carcinoma, breast, magnetic resonance imaging, diffusion magnetic resonance imaging,
positron emission tomographyBackground
Breast cancer is a heterogeneous tumor that exhibits vari-
ous patterns of progression, results and treatment
responses. The management plans for breast cancer are
determined in accordance with the preoperative tumor-
nodes-metastasis (TNM) stage, histologic classification of
postoperative TNM stage, and the levels of hormone* Correspondence: rad-ksh@hanmail.net
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reproduction in any medium, provided the orreceptor and molecular markers in the specimens [1]. Pre-
dicting the prognosis of breast cancer is very important for
determining the direction of treatment; the conventional
prognostic factors include tumor nuclear grade, tumor size,
and the presence of lymph node metastasis. The immuno-
histochemical prognostic factors include hormone recep-
tors such as estrogen receptor (ER), progesterone receptor
(PR), human epidermal growth factor receptor 2 (HER2),
and Ki-67. The role of 18F-fluorodeoxygluxose positron
emission tomography/computed tomography (FDG PET/d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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increase in cancer cell glycolysis, and it is used for the diag-
nosis of lesions, staging, recurrence, and treatment
response [1]. FDG uptake aids in predicting the prognosis
for primary breast cancer and is associated with several
histopathological and immunohistochemical prognostic
factors [2,3]. The diffusion-weighted image (DWI) is a mo-
dality used to evaluate the microstructural characteristics of
water diffusion in biological tissues [4]. The apparent diffu-
sion coefficient (ADC) is calculated by DWI. Malignant
tumors with highly cellular lesions display low ADC values
due to the inverse relationship with tumor cellularity [5,6].
Therefore, ADC is useful for distinguishing malignant and
benign tumors, and DWI is useful for evaluating the
tumor’s response to treatment. However, few studies on the
association between ADC values and prognostic factors
have been published, and some researchers say that there is
no association [5,6]. FDG PET/CT and DWI are both func-
tional modalities that indirectly represent the biological
characteristics of cancer, but there are few studies exploring
the association between the two modalities and prognostic
factors [1]. Our study attempted to evaluate the mutual as-
sociation by comparing the prognostic factors, maximum
standardized uptake value (SUVmax) value of PET/CT, and
ADC values associated with diffusion imaging.Methods
Patients
From the pathology database, among the patients who
had been confirmed with IDC through biopsies and sur-
geries from June 2008 to January 2010, the names of
patients who had received DWI and PET/CT and under-
gone surgeries were collected. From these patients, ones
who had received preoperative chemotherapies or
adjuvant chemotherapies; ones who, although they had
been diagnosed with breast cancer through ultrasound
or mammography, had not shown lesions in magnetic
resonance imaging (MRI) or PET/CT; and ones who had
recurrences during postoperative follow-ups were all
excluded. From that total of 142 patients, and excluding
the 24 patients who showed non-mass in their MRI
scans, 118 patients were included in this study.Imaging acquisition
The MRI images were acquired with a 1.5 T scanner
(Achieva; Philips Medical Systems, Best, The Nether-
lands) and a 3.0 T scanner (Magnetom Verio; Siemens
Medical Solutions, Erlangen, Germany) equipped with a
breast coil. The MRI images with the Achieva scanner
were performed using the following sequences: sagittal,
fat-suppressed, fast spin-echo T2-weighted imaging
sequence; axial DWI with a single-shot echo-planar im-
aging (EPI) with b factors of 0 and 1000 second/mm2;pre- and dynamic axial T1-weighted three-dimensional,
fat-suppressed, fast spoiled gradient-echo sequence.
The MRI images from the Verio scanner were
acquired using the following sequences: axial, turbo
spin-echo T2-weighted imaging sequence; axial DWI
with echo-planar imaging (EPI) with b factors of 0
and 750 seconds/mm2; pre- and post-contrast, axial
T1-weighted fast low-angle shot (FLASH) three-
dimensional, volume interpolated breath-hold examin-
ation (VIBE) sequence.
PET/CT studies were acquired on combined PET/CT
in-line systems, either Biograph Duo or Biograph True-
point (Siemens Medical Solutions, Knoxville, TN, USA).
The acquisition time was two to three minutes per bed
position. All patients were in supine position during
PET/CT scanning. CT began at the orbitomeatal line
and progressed to the proximal thigh (130 kVp, 80 mAs,
and 5 mm slice thickness; 120 kVp, 50mAs, and 5 mm
slice thickness). A PET scan followed immediately over
the same body region. The CT data were used for
attenuation correction, and images were reconstructed
using a standard ordered-subset expectation maximization
(OSEM) algorithm. The axial spatial resolution was
6.5 mm or 4.5 mm at the center of the field of view,
respectively.
Image analysis
DWIs were obtained along each of the x-, y- and z-axes.
The ADC value was calculated according to the formula:
ADC ¼ 1= b2 b1ð Þ½ ln S2=S1ð Þ , where S1 and S2 are
the signal intensities in the regions of interest (ROI)
obtained by two gradient factors, b2 and b1 (b1 = 0 and
b2 = 1000 s/mm2 for the 1.5 T scanner; b1 = 0 and
b2 = 750 s/mm2 for the 3.0 T scanner). For the measure-
ment of the ADC value, one radiologist with four years’
experience of breast MRI manually placed a region of
interest (ROI) that was slightly smaller than the solid
portion of the tumor to ensure that cystic, necrotic por-
tions of normal parenchyma were not included [1,3,5].
The mean ADC values were obtained.
One radiologist with six years’ experience of breast
MRI reviewed the PET/CT report paper and SUVmax of
the breast cancer was used.
Histologic analysis
Pathologic reports were reviewed to determine the size,
lymph node metastasis, and histologic grade. Immuno-
histochemistry was used to test for the expression of the
following molecular markers: estrogen receptor (ER),
progesterone receptor (PR), human epidermal growth
factor receptor 2 (HER2), Ki-67, and epidermal growth
factor receptor (EGFR). ER and PR positivity was defined
as the presence of 10% or more positively stained nuclei
in ten high-power fields. The intensity of c-erbB-2
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or 3+ scores were classified as HER2 positive, and
tumors with 0 or 1+ were negative. EGFR was consid-
ered positive if membrane staining was observed. Ki-67
of>=15% was considered positive expression.Statistical analysis
Data are presented as the median and range for continu-
ous variables and frequency with percentage for categor-
ical variables.
To examine whether the ADC value and SUVmax
value can provide prognostic information, the difference
in ADC values and SUVmax values of each prognostic
group was analyzed. In cases in which the prognostic
groups were classified as the positive group and the
negative group, the Mann–Whitney U test and Kruskal-
Wallis for variables with non-normal distribution were
used. To evaluate the correlation between ADC value
and SUVmax, Spearman’s correlation coefficient was
used. The statistical analyses above were performed with
SAS software, version 9.1 (SAS Institute Inc. Cary, NC,
USA). A two-tailed P value of <0.05 was considered sta-
tistically significant.
Written informed consent was obtained from the pa-
tient for publication of this report and any accompany-
ing images.Results
The mean age of 118 patients was 52 years (range, 29 to
81 years). The mean value of tumor size, ADC mean
and SUVmax was 27.5 ± 21.7 mm, 994.3 ± 217.0X10-
6 mm2/s and 4.4 ± 3.8 (mean ± SD), respectively.
Histologic analysis was invasive ductal carcinoma
(IDC) in 32 patients (27%) and IDC with ductal carcin-
oma in situ (DCIS) in 86 patients (73%). Histologic
grades consisted of 33% (39/118) well differentiated, 50%
(59/118) moderate, and 17% (20/118) poorly differen-
tiated. In the immunohistochemical study, ER and PR
positives were 89 patients (76%) and 74 patients (63%),
respectively; HER2 positives were 50 patients (43%);
EGFR were 23 patients (20%). Ki-67 was 25% on
average.
In the statistical analysis, the ADC mean showed
statistically significant low values in the ER-positive
expression group and HER2-negative expression
group (P <0.05) (Table 1, Figure 1). The high SUV-
max was shown to have correlations with the large
tumor sizes, lymph node (LN) metastasis positives,
high histologic grades, ER-negative expression, PR-
negative expression, EGFR-positive expression, and
high Ki-67 (Table 1, Figure 2). There was no correl-
ation between the ADC mean and SUVmax
(P = 0.786). The correlation coefficient r was −0.025.Discussion
Both diffusing MR imaging and FDG PET/CT can pro-
vide important functional information for IDC with high
cellularity. Diffusion MR imaging can provide informa-
tion about the random water motion in tissues, and have
a potential roles in the characterization of malignancy,
including determination of lesion aggressiveness and
monitoring response to therapy [5,7-10]. PET/CT visua-
lizes the metabolic activities of tissue and provides infor-
mation about the rate of glucose metabolism [2]. FDG
PET/CT can detect enhanced glycolysis of breast cancer
cells and can be used for diagnosing, staging, detecting
recurrence, and assessing response to therapy [1,2]. Both
diffusion MR imaging and FDG PET/CT may be related
to tumor cellularity. Areas of high cellularity have more
structures and cell membranes resulting in impedance of
water motion, and have increased cellular proliferation.
Therefore, ADC values are low and FDG uptake gets
higher in high cellular tumors [11]. In contrast, areas
with low cellularity are less resistant to water diffusion
resulting in higher ADC value; scarce proliferative activ-
ity resulting in lower FDG uptake [11].
Correlation between ADC value and prognostic factors
We studied the correlation between mean ADC value
and prognostic factors such as tumor size, LN metastasis,
histologic grade, age, and expression levels of ER, PR,
HER2, EGFR, and Ki-67. Significant associations were
noted between mean ADC and positive ER status
(P= 0.009) and negative HER2 status (P= 0.016), which is
similar to the results reported by Jeh et al. [6]. The ADC
value is useful for the differentiation of malignant masses
from benign masses or normal breast tissue, as malignant
tumors have lower ADC values compared to benign
masses [7,12-15]. Hatakenaka et al. [8] reported that the
ADC value differed significantly between invasive and
non-invasive ductal cancer. ER expression is associated
with a favorable prognosis [16-18]. Tumors that display
positive ER and PR expression respond well to adjuvant
and palliative hormone therapy [4]. Ludovini et al. [19]
explained that the reason for the lower ADC values
observed in the ER-positive group as compared to the
ER-negative group is that ER blocks the angiogenic path-
way and reduces perfusion, which in turn affects the
ADC value. Notably, HER2 is similar in structure to the
human epidermal growth factor receptor (EGFR). When
overexpressed, it inhibits the control mechanisms in nor-
mal cells, accelerates cell growth and division and can
cause cancer. HER2-positive cells that are more likely to
exhibit a malignant phenotype, accompanied by cell pro-
liferation, invasion and metastasis [4,6]. In addition to
cell growth, HER2 induces angiogenesis; thus, blood flow
increases in tumors that are HER2 positive and hormone
receptor negative [16]. Reduced perfusion in the HER2-
Table 1 Associations of SUVmax and ADC with clinicopathologic prognostic factors in invasive ductal carcinoma
Factor Number of cases (n = 118) ADC mean (X 10–6 mm2/s) P value SUVmax P value
Tumor size (mm)
<20 49(41.88) 942.3(412.3-1793.7) 0.185 1.9(0–8.9) <0001
20-50 57(48.72) 969.3(599.8-1555.5) 4.7(0–20.5)
>50 11(9.40) 1061.2(661.4-1402.9) 5.1(1.2-15.2)
LN metastasis
negative 76(65.0) 970.2(412.3-1793.7) 0.655 2.5(0–18.7) 0.003
positive 41(35.0) 962.1(599.8-1555.5) 4.8(1.2-20.5)
Histologic grade
1 39(33.3) 962.9(412.3-1793.7) 0.832 2.1(0–10.5) <0001
2 58(49.57) 966.7(565.2-1555.5) 2.9(0–18.7)
3 20(17.1) 955.3(666.5-1402.9) 7.1(2.6-20.5)
ER
negative 28(23.9) 1043.6(764.1-1402.9) 0.009 5.3(0–18.7) 0.003
positive 89(76.1) 946.5(412.3-1793.7) 2.8(0–20.5)
PR
negative 43(36.8) 1012.99(753.5-1405.5) 0.055 4.6(0–20.5) 0.035
positive 74(63.3) 947.6(412.3-1793.7) 2.8(0–14.1)
HER 2
negative 67(57.26) 922.3(412.3-1793.7) 0.016 2.9(0–16.1) 0.529
positive 50(42.74) 1019.8(599.8-1555.5) 3.7(0–20.5)
EGFR
negative 92(80.0) 962.3(412.3-1793.7) 0.321 2.7(0–20.5) 0.001
positive 23(20.0) 1041.0(666.5-1402.9) 5.3(1.3-18.7)
Ki-67
<15 50(42.7) 962.7(412.3-1793.7) 0.998 2.3(0–8.6) 0.001
≥15 67(57.3) 969.3(568.4-1402.9) 4.8(0–20.5)
Age
<50 59(50.4) 971.1(412.3-1555.5) 0.577 3.2(0–16.1) 0.301
≥50 58(49.6) 959.6(565.2-1793.7) 3.0(0–20.5)
* ADC, apparent diffusion coefficient; EGFR, epidermal growth factor receptor; ER, estrogen receptor: HER2, human epidermal growth factor receptor 2; LN, lymph
node; PR, progesterone receptor; SUVmax, maximum standardized uptake value.
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ADC values. Kim et al. [4] reported that ADC values
were higher in tumors with increased HER2 expression,
although there was no significant correlation between
HER2 expression and ADC values.
There was no correlation between mean ADC value and
histologic grade as determined by Ki-67 expression. Not-
ably, one of the important indices of histologic tumor
grade is tumor cellularity [6,14]. Ki-67 is a marker of
tumor cellularity and is a benign nuclear antigen found in
proliferative-phase cells [6,14]. Tumor grade and Ki-67 ex-
pression are also related to other proliferative diseases and
recurrences [17], and cancer of lower cellularity is asso-
ciated with improved prognosis [20]. Diffusion is difficult
in areas of dense tumor cellularity because of the effectivemotion of water molecules [13]. There are some reports of
a negative correlation between ADC values and tumor cel-
lularity [7,8,15,21]. Woodhams et al. [21] reported that
DWI is a unique marker of tumor cellularity. However,
Yoshikawa et al. [22] and Kim et al. [4] reported that
ADC value and tumor cellularity are not correlated. Previ-
ous reports found no correlation between Ki-67 expres-
sion and ADC value [6].
ADC mean was not correlated with LN metastasis.
Breast cancer with ipsilateral axillary lymph node metas-
tasis is the most important predictor of long-term
survival [23,24]. In the case of LN metastasis, the prog-
nosis is poor, with the prognosis worsening as the
number of LN metastases increases [7]. The presence of
LN metastasis is most important in conjunction with
Figure 1 A 65-year-old woman with invasive ductal carcinoma
of the right breast. On immunohistochemical study, ER and PR
were negative. (A) ADC map shows ROI for measuring the mean
ADC value. The calculated ADC value was 862× 10-6 mm2/s, which
was lower than mean ADC value (994 × 10-6 mm2/s). (B) Axial
enhanced T1-weighted image after two minutes of contrast
injection demonstrates a spiculated enhancing mass in the right
breast. (C) FDG PET/CT image shows FDG uptake in the right breast
with measured SUVmax as 7.3. ADC, apparent diffusion coefficient;
ER, estrogen receptor: FDG PET/CT, 18 F-fluorodeoxygluxose positron
emission tomography/computed tomography; PR, progesterone
receptor, ROI, region of interest.
Figure 2 A 65-year-old woman with poorly differentiated
invasive ductal carcinoma of the left breast. (A) On ADC
map, calculated ADC value by ROI was 822 × 10-6 mm2/s,
which was lower than mean ADC value (994 × 10-6 mm2/s). (B)
Axial enhanced T1-weighted image demonstrates an irregular
spiculated mass in the left breast. (C) FDG PET/CT image shows
FDG uptake in the left breast. Measured SUVmax of breast
cancer is 7.3. On histologic examination, axillary LN metastasis
was noted in one LN. The results of immunohistochemical
study were ER (−), PR (−), HER2 (−), EGFR (+) and Ki-67 70%.
ADC, apparent diffusion coefficient; EGFR, epidermal growth
factor receptor; ER, estrogen receptor: FDG PET/CT, 18
F-fluorodeoxygluxose positron emission tomography/computed
tomography; HER2, human epidermal growth factor receptor 2;
LN, lymph node; PR, progesterone receptor; SUVmax, maximum
standardized uptake value.
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proceed with conservative therapy [7]. Some authors
have reported a correlation between LN metastasis and
ADC value; the ADC value can help in avoiding un-
necessary surgical staging of axillary LN [1,7]. However,
Kim et al. [4] found no association between ADC and
LN metastasis, which is similar to our results.
ADC values and tumor size were not correlated
(P= 0.185). Tumor size is a very important factor in the
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increases, the likelihood of metastasis increases, and the
overall survival rate decreases [7]. Although Kim et al.
[4] and Nakajo et al. [1] stated that ADC and tumor size
are not correlated, Kuroki-Suzuki et al. [9] stated that
there is a significant correlation among ADC, pT1 and
pT2-4. Razek et al. [7] also reported a correlation be-
tween tumor size and ADC. Based on a hypothesis that
small lesions of less than 1 cm are difficult to detect in
DWI, Razek et al. excluded lesions less than 1 cm in
size. Because lesions less than 1 cm in size were not
excluded in this study, which resulted in a difference in
mean tumor size, comparison with the results obtained
by Razek et al. [7] is difficult (in this study, the mean
was 2.8 ± 2.2 cm; in the study by Razek et al., the mean
was 3.9 ± 2.0 cm).
Correlation between SUVmax and prognostic factor
SUVmax were associated with numerous prognostic fac-
tors such as tumor size, LN metastasis, histologic grade,
and expression levels of ER, PR, EGFR, and Ki-67 among
others; these findings are similar to those reported by
previous studies [1-3,25]. Oshida et al. [2] used differen-
tial absorption ratio (DAR) as the FDG uptake index; the
high DAR group demonstrated significantly worse prog-
noses with respect to both overall and relapse-free sur-
vival. Ueda et al. [25] stated that a high SUVmax is
associated with higher relapse and mortality rates.
Correlation between ADC mean and SUVmax
Mean ADC and SUVmax were not correlated (P= 0.786).
There were reports of ADC values decreasing due to the
fact that water diffusion becomes difficult in regions of
high tumor cellularity. Furthermore, ADC and tumor
cellularity are inversely proportional [7,8,15,21]. Several
authors have reported that FDG uptake and cellularity
are positively correlated [26,27]. Because SUVmax and
ADC were expected to be inversely proportional to each
other, the existence of any correlation between the results
obtained with both modalities is currently being investi-
gated further. Nakajo et al. [1] reported that the SUV
values and ADC values were inversely proportional in
the context of malignancy. Ho et al. [5] stated in their
study of primary cervical cancer that SUVmax and ADC
mean were not correlated. Our study used a larger sam-
ple size than that used by Nakajo et al. [1] and Ho et al.
[5]. In contrast to the study performed by Nakajo et al.
[1], our study did not separate the prognostic group into
a ‘better’ group and a ‘worse’ group. In contrast to Nakajo
et al. [1], who included only DCIS, our study only used
IDC as subjects. Because the study by Ho et al. [5] inves-
tigated cervical cancer, the subjects differed from those
included in the present study. The accurate identification
of a clinical correlation between DWI and PET/CTrequires further evaluations involving a variety of sub-
jects. For now, the two modalities cannot be considered
as interchangeable.
This study has some limitations. First, because there
were many cases in which ADC values were difficult to
measure for non-mass lesions, 24 lesions were excluded
due to inaccuracy of the ROI measurement. Due to the
variation in histologic values, this exclusion of lesions
may have introduced variability to the study. Second, al-
though detecting lesions less than 1 cm was considered
difficult with DWI, this study included all such small
lesions; however, ACD values were not measured in
these small lesions. Third, there was no correlation
established between the histologic prognostic factors and
the actual clinical prognosis follow-up. Further evalua-
tions that complement these limitations are necessary.
Conclusion
The ADC values were associated with several prognostic
factors of IDC (tumor size, Ki-67, age, and so on.). The
SUVmax was associated with multiple prognostic factors
including the tumor size, LN metastasis, histologic
grade, ER, PR, EGFR, Ki-67, and so on. DWI and FDG
PET/CT are different image modalities representing dif-
ferent biologic aspects of cancer. Even though there was
no association between the ADC values and SUVmax in
IDC, these two modalities might play a complementary
role in detecting the prognosis of IDC.
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